Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals develops DNA medicines to treat and protect against diseases associated with HPV, cancer, and infectious diseases. Its products include VGX-3100, INO-3107, INO-3112, INO-5401, INO-4201, INO-4800, and INO-6160, all in various stages of clinical trials. The company has partnered with numerous organizations, including government agencies, foundations, and biopharmaceutical companies. Inovio was incorporated in 1983 and is headquartered in Pennsylvania.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

2.3 USD

Potential

-100%

Strengths

Price to book ratio (1.19) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.5